Mered Parnes

Dr. Mered Parnes

Baylor College of Medicine, Houston, Texas, USA
+2
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
PDF file
MHMariam Hull
Mariam Hull
MPMered Parnes
Mered Parnes

1 October 2021 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
MHMariam Hull
Mariam Hull
MPMered Parnes
Mered Parnes
Joseph JankovicJoseph Jankovic
Joseph Jankovic
Background and Objectives Functional (psychogenic) movement disorders (FMDs) are conditions in which affected patients develop abnormal movements that are incongruous with known, organic, movement disorders, often associated with psychological stressors. Methods In this case series, electronic medical records of all patients who presented to our adult and pediatric tertiary care movement disorders clinics between March 1 and October 30, 2020, and during the same period in 2019 were reviewed. All patients diagnosed with functional (psychogenic) movement disorder were included if they satisfied diagnostic criteria. Results Among 550 new patients referred for evaluation at our tertiary care movement disorders centers, 45 (8.2%) received a diagnosis of FMD; 75.6% were female, in comparison to the prior year during which time 665 new patients were evaluated and 5.1% were diagnosed with FMD. This represents a 60.1% increase (90.1% in pediatric cohort, 50.9% in adult cohort) in new patients diagnosed with FMD during the COVID-19 pandemic. Conclusions Within our patient population, there has been increased incidence of FMDs in the setting of the COVID-19 pandemic, possibly reflecting increased psychological and other stressors during this period.

20 June 2022 in Movement Disorders
Verified
Journal Article
Open access
TWThomas Wirth
Thomas Wirth
GGGiacomo Garone
Giacomo Garone
MKManju A Kurian
Manju A Kurian
APAmélie Piton
Amélie Piton
FMFrancisca Millan
Francisca Millan
MAMathieu Anheim
Mathieu Anheim
Background: Most reported patients carrying GNAO1 mutations showed a severe phenotype characterized by early‐onset epileptic encephalopathy and/or chorea.Objective: The aim was to characterize the clinical and genetic features of patients with mild GNAO1‐related phenotype with prominent movement disorders.Methods: We included patients diagnosed with GNAO1‐related movement disorders of delayed onset (>2 years). Patients experiencing either severe or profound intellectual disability or early‐onset epileptic encephalopathy were excluded.Results: Twenty‐four patients and 1 asymptomatic subject were included. All patients showed dystonia as prominent movement disorder. Dystonia was focal in 1, segmental in 6, multifocal in 4, and generalized in 13. Six patients showed adolescence or adulthood‐onset dystonia. Seven patients presented with parkinsonism and 3 with myoclonus. Dysarthria was observed in 19 patients. Mild and moderate ID were present in 10 and 2 patients, respectively.Conclusion: We highlighted a mild GNAO1‐related phenotype, including adolescent‐onset dystonia, broadening the clinical spectrum of this condition. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

6 October 2018 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PDF file
MPMered Parnes
Mered Parnes
HBHassaan Bashir
Hassaan Bashir
JJJoseph Jankovic
Joseph Jankovic
Background: Since its localization to the NKX2‐1 gene in 2002, the phenotype of the disorder historically called “benign hereditary chorea” has been expanding beyond chorea.Methods: The phenomenology of movement disorders and other symptomatology associated with mutations in NKX2‐1 were characterized after a detailed evaluation of consecutive patients evaluated in our clinic over the past 3 years.Results: We studied 5 patients (3 females), ages 2 to 31 years, with confirmed pathogenic variants in NKX2‐1. All patients exhibited chorea, gross motor delay, and gait impairment. Other symptoms included neonatal respiratory failure (n = 4), cognitive deficits (n = 3), hypothyroidism (n = 4), joint laxity (n = 2), myoclonus (n = 1), hypotonia (n = 3), and seizures (n = 1). Chorea often proved refractory to medical therapies.Conclusions: The phenotype associated with pathogenic variants in NKX2‐1 frequently includes disabling and often medically refractory neurological and non‐neurological abnormalities. We therefore suggest that the term benign hereditary chorea be abandoned in favor of its genetic designation as NKX2‐1–related disorder.

18 June 2024 in Movement Disorders
Verified
Journal Article
Open access
MSMarianna Sarchioto
Marianna Sarchioto
JFJessica Frey
Jessica Frey
CGChristos Ganos
Christos Ganos
DGDonald L. Gilbert
Donald L. Gilbert
AHAndreas Hartmann
Andreas Hartmann
TSthe Tic Disorders Study Group of the International Parkinson's and Movement Disorders Society
the Tic Disorders Study Group of the International Parkinson's and Movement Disorders Society

25 September 2023 in Genes
Verified
Journal Article
Open access
PDF file
LHLea Hentrich
Lea Hentrich
MPMered Parnes
Mered Parnes
TLTimothy Edward Lotze
Timothy Edward Lotze
RCRohini Coorg
Rohini Coorg
TKTom J. de Koning
Tom J. de Koning
HDHormos Salimi Dafsari
Hormos Salimi Dafsari
Biallelic variants in the Golgi SNAP receptor complex member 2 gene (GOSR2) have been reported in progressive myoclonus epilepsy with neurodegeneration. Typical clinical features include ataxia and areflexia during early childhood, followed by seizures, scoliosis, dysarthria, and myoclonus. Here, we report two novel patients from unrelated families with a GOSR2-related disorder and novel genetic and clinical findings. The first patient, a male compound heterozygous for the GOSR2 splice site variant c.336+1G>A and the novel c.364G>A,p.Glu122Lys missense variant showed global developmental delay and seizures at the age of 2 years, followed by myoclonus at the age of 8 years with partial response to clonazepam. The second patient, a female homozygous for the GOSR2 founder variant p.Gly144Trp, showed only mild fine motor developmental delay and generalized tonic–clonic seizures triggered by infections during adolescence, with seizure remission on levetiracetam. The associated movement disorder progressed atypically slowly during adolescence compared to its usual speed, from initial intention tremor and myoclonus to ataxia, hyporeflexia, dysmetria, and dystonia. These findings expand the genotype–phenotype spectrum of GOSR2-related disorders and suggest that GOSR2 should be included in the consideration of monogenetic causes of dystonia, global developmental delay, and seizures.